Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2020Website:
http://www.tarsusrx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:10:24 GMTDividend
Analysts recommendations
Institutional Ownership
TARS Latest News
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions. Strong financials with $323M in cash reserves, a healthy current ratio, and a projected positive cash flow by Q3 2024 support robust growth.
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with a $1 billion market opportunity in the initial addressable segment alone. TARS has promising data in trials for various conditions, including Lyme disease and Meibomian gland disease, with potential preventive and therapeutic benefits.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - Barclays Eddie Hickman - Guggenheim Securities Operator Good afternoon. And welcome to the Tarsus' Second Quarter 2024 Financial Results Conference Call.
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago.
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update.
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences:
The average price target suggests a potential 38.7% increase for Tarsus Pharmaceuticals (TARS). Although studies have shown this metric may not always be reliable, an increase in earnings estimates could indicate a potential uptick in the stock's value soon.
The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 1(current)
What type of business is Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
What sector is Tarsus Pharmaceuticals in?
Tarsus Pharmaceuticals is in the Healthcare sector
What industry is Tarsus Pharmaceuticals in?
Tarsus Pharmaceuticals is in the Biotechnology industry
What country is Tarsus Pharmaceuticals from?
Tarsus Pharmaceuticals is headquartered in United States
When did Tarsus Pharmaceuticals go public?
Tarsus Pharmaceuticals initial public offering (IPO) was on 16 October 2020
What is Tarsus Pharmaceuticals website?
https://www.tarsusrx.com
Is Tarsus Pharmaceuticals in the S&P 500?
No, Tarsus Pharmaceuticals is not included in the S&P 500 index
Is Tarsus Pharmaceuticals in the NASDAQ 100?
No, Tarsus Pharmaceuticals is not included in the NASDAQ 100 index
Is Tarsus Pharmaceuticals in the Dow Jones?
No, Tarsus Pharmaceuticals is not included in the Dow Jones index
When was Tarsus Pharmaceuticals the previous earnings report?
No data
When does Tarsus Pharmaceuticals earnings report?
The next expected earnings date for Tarsus Pharmaceuticals is 08 November 2024